To determine the rate of bone mass loss and the risk of fracture induced by androgen deprivation therapy in patients with prostate cancer.
Prospective study in 2 phases. In the first phase, demographic variables, FRAX(®), bone mineral density and clinical fractures were collected, before starting the therapy and up to 1 year after ending the therapy.